These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34097173)

  • 1. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
    Correale M; Petroni R; Coiro S; Antohi EL; Monitillo F; Leone M; Triggiani M; Ishihara S; Dungen HD; Sarwar CMS; Memo M; Sabbah HN; Metra M; Butler J; Nodari S
    Heart Fail Rev; 2022 Jul; 27(4):1147-1163. PubMed ID: 34097173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):381-393. PubMed ID: 35876091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB
    Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of SGLT2 inhibitors (gliflozins) in heart failure].
    Scheen AJ; Ancion A; Lancellotti P
    Rev Med Suisse; 2022 Aug; 18(792):1546-1550. PubMed ID: 36004654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction.
    Haluzík M; Kubíčková M; Veselý J; Linhart A; Prázný M; Škrha J; Táborský M; Málek F
    Vnitr Lek; 2021; 67(7):404-411. PubMed ID: 35459358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dapagliflozin in DELIVER : confirmation of the benefit with SGLT2 inhibitors in heart failure with preserved ejection fraction].
    Scheen A; Lancellotti P
    Rev Med Liege; 2023 Feb; 78(2):79-84. PubMed ID: 36799324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 15. SGLT2 inhibitors - a new pillar for the treatment of heart failure.
    Tavačová D; Václavík J
    Vnitr Lek; 2021; 67(8):475-478. PubMed ID: 35459367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 17. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction.
    Elserafy AS; Reda A; Farag E; Mostafa T; Farag N; Elbahry A; Sanad O; Bendary A; Elkersh A; Attia I; Selim M; Khamis H; Issak ER
    Clin Drug Investig; 2021 Dec; 41(12):1027-1036. PubMed ID: 34780022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
    Severino P; D'Amato A; Prosperi S; Costi B; Angotti D; Birtolo LI; Chimenti C; Lavalle C; Maestrini V; Mancone M; Fedele F
    Heart Fail Rev; 2023 May; 28(3):709-721. PubMed ID: 34654997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.